• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Pfizer

Pfizer

PACE International Fixed Income C PWFCX 2 Star

Last Price$9.70Day Change (%)0.10%
Open Price$9.70Day Change ($)0.01
Day Range9.70–9.7052-Week Range9.49–10.98

As of Fri 03/24/2017 | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Pfizer Receives Positive CHMP Opinion for TRUMENBA® for Prevention of Meningococcal Group B Disease

    Pfizer Receives Positive CHMP Opinion for TRUMENBA® for Prevention of Meningococcal Group B Disease

  2. Pfizer Files 8K - Other Events

    Pfizer Files 8K - Other Events

  3. Press Release: FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma

    Press Release: FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma

  4. Servier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia

    Servier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia

  5. Bristol-Myers Squibb and Pfizer to Present New Analyses of Eliquis™ (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session

    Bristol-Myers Squibb and Pfizer to Present New Analyses of Eliquis™ (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session

  6. Press Release: FDA Grants Approval for -2-

    Press Release: FDA Grants Approval for -2-

  7. Press Release: FDA Grants Approval for -3-

    Press Release: FDA Grants Approval for -3-

  8. Health Care Slightly Higher as House Vote Postponed -- Health Care Roundup

    Health Care Slightly Higher as House Vote Postponed -- Health Care Roundup

  9. Global Thyroid Gland Disorder Treatment Market to Witness Growth, Owing to Increase in Awareness Programs: Technavio

    Global Thyroid Gland Disorder Treatment Market to Witness Growth, Owing to Increase in Awareness Programs: Technavio

  10. Chi-Med appoints Dr Weiguo Su, Chief Scientific Officer, to Board of Directors

    Chi-Med appoints Dr Weiguo Su, Chief Scientific Officer, to Board of Directors

12345

©2017 Morningstar Advisor. All right reserved.